Does FEHB Cover Zepbound? 2026 Plan-by-Plan Guide
By The RX Index Editorial Team · Last verified: · Reading time: ~12 minutes
Editorial Standards · Affiliate Disclosure · Sources: OPM, fepblue.org, GEHA GLP-1 FAQ, CVS Caremark, Express Scripts
Disclosure: Some links on this page are affiliate links. If you purchase through these links, we may earn a commission at no extra cost to you.
The bottom line, before you scroll
Does FEHB cover Zepbound? Yes — conditionally. Every FEHB plan must cover at least one FDA-approved anti-obesity GLP-1, but in 2026 almost no major FEHB plan treats Zepbound as a standard preferred drug. OPM’s mandate is satisfied by Wegovy on most plans. Zepbound requires a formulary exception on BCBS FEP, GEHA, MHBP, and most Aetna FEHB plans — all of which use CVS Caremark, which made Wegovy the preferred GLP-1 in July 2025.
- BCBS FEP (all three plans): Formulary exception required — Tier 3 non-preferred (Standard/Basic) or Tier 2 if Focus exception approved.
- GEHA (all five plans): Non-formulary across the board. Formulary exception required with preferred-alternative hurdle.
- Kaiser Permanente FEHB: Prior authorization + 50% coinsurance. No CVS Caremark involvement — easier bar than formulary exception, but regional rules vary.
- APWU High Option: Friendliest major FEHB path — Express Scripts kept Zepbound on its National Preferred Formulary. Standard PA only.
- Compass Rose: Subcutaneous solution excluded (Tier E). Auto-injector is Tier 3 with PA and quantity limits.
If your plan blocks Zepbound, your three real options are: (1) file a formulary exception with your prescriber’s documentation, (2) go self-pay via LillyDirect at $299–$449/month with no prior authorization, or (3) move to Wegovy — which every major FEHB plan covers.
Skip the paperwork — Ro handles FEHB prior authorization for you
Ro states that FEHB members can join Ro Body and access its insurance concierge — the team that contacts your plan, runs a coverage check, and submits prior-authorization paperwork on your behalf. The free GLP-1 Insurance Coverage Checker takes a few minutes; the report arrives after the check completes.
Run the free Ro GLP-1 Insurance Coverage Checker →Disclosure: The RX Index may earn a commission if you sign up with Ro through our link, at no additional cost to you. Our FEHB plan analysis is based on plan and PBM documents, not affiliate status.
What your FEHB drug-cost tool is telling you (and what it actually means)
Before you call your doctor or the plan, learn to read the tool. This 30-second table saves most people a confused phone call.
| What your FEHB drug-cost tool says | What it actually means | What to do next |
|---|---|---|
| “Covered with PA” | Zepbound is on the formulary, but your prescriber must document plan criteria first. | Ask your prescriber to submit a prior authorization with BMI, comorbidities, and prior weight-loss medication trials. |
| “Non-formulary” | Zepbound isn’t on your plan’s standard list. Coverage is exception-based. | Ask your prescriber to submit a formulary exception — a higher bar than PA. |
| “Excluded” or “Tier E” | The plan won’t cover Zepbound under standard rules. Some plans still allow exception or appeal pathways. | Read the denial reason carefully. Submit an exception or appeal with documentation, or move to self-pay. |
| “Preferred alternative listed” (usually Wegovy) | The plan wants you to try Wegovy first. | Ask whether you must complete a Wegovy trial before Zepbound is reviewable. Most CVS Caremark FEHB plans require this. |
| Cost shows “$0” or seems too low | The tool may be ignoring step therapy, formulary exception requirements, or quantity limits. | Re-run with the exact NDC/formulation and your actual pharmacy. Confirm with member services. |
The 2026 FEHB Zepbound Coverage Reality Matrix
Built by reading each plan’s 2026 published pharmacy documentation and cross-referencing each carrier’s PBM formulary. Refreshed quarterly and during every Open Season.
Last verified: Next refresh: July 28, 2026.
| FEHB / PSHB Plan | 2026 Zepbound Status | Coverage Path | Wegovy 2026 | PBM | What This Means For You |
|---|---|---|---|---|---|
| BCBS FEP Blue Standard | Tier 3 non-preferred (FE only) | Formulary Exception required | Non-preferred (PA required) | CVS Caremark | Default GLP-1 path is Wegovy. Zepbound only after meeting FEP’s criteria. No tier exception allowed. |
| BCBS FEP Blue Basic | Managed Not Covered → Tier 3 with FE | Formulary Exception required; without FE, pays full retail | Non-preferred (PA required) | CVS Caremark | Hardest BCBS path. Without exception, full list price (~$1,000–$1,500/month). |
| BCBS FEP Blue Focus | Tier 2 Preferred (with approved FE) | Formulary Exception required (closed formulary) | Tier 2 Preferred (with FE) | CVS Caremark | If exception approved, you get the better tier — but the closed formulary means everything off-list needs an exception first. |
| GEHA High | Non-formulary | Formulary Exception required | Non-preferred (PA required) | CVS Caremark | Check expiration on any 2025 approval. A new 2026 FE may be required for continued coverage. |
| GEHA Standard | Non-formulary | Formulary Exception required | Non-preferred (PA required) | CVS Caremark | Same path as High. Forum users report ~$550/month after FE approval — member-reported, not official. Verify with GEHA drug-cost tool. |
| GEHA HDHP | Non-formulary | Formulary Exception required | Non-preferred (PA required) | CVS Caremark | The HDHP deductible applies before coinsurance — Zepbound can cost significantly more in the first months of the year. |
| GEHA Elevate | Non-formulary | Formulary Exception required | Preferred (PA required) | CVS Caremark | Wegovy is the preferred GLP-1 here — unique among GEHA plans. Path of least resistance is starting Wegovy first. |
| GEHA Elevate Plus | Non-formulary | Formulary Exception required | Non-preferred (PA required) | CVS Caremark | Same Zepbound path as the High/Standard tier. |
| Kaiser Permanente FEHB (all regions) | PA + 50% coinsurance | Prior Authorization + 50% coinsurance | Same: PA, 50% coinsurance | Kaiser internal | Different model — no CVS Caremark. PA, not FE. Lifestyle program enrollment required. Zepbound-specific rules vary by region. |
| Kaiser Northwest (verified) | Non-formulary, clinical review | Clinical review required; tighter than all-regions summary | Same | Kaiser internal | Northwest is the strictest verified Kaiser region. Don’t assume your Kaiser region matches the all-regions summary. |
| MHBP (Mail Handlers) | Not on standard anti-obesity formulary | Preferred alternatives required first; exception possible | Wegovy preferred; Saxenda, Qsymia, orlistat also listed | CVS Caremark | CVS Weight Management Program enrollment required to fill at plan cost share. Do not switch into MHBP for Zepbound. |
| Compass Rose Health Plan | Solution: Tier E (Excluded)Auto-injector: Tier 3 PA + QL | Auto-injector path reachable with PA; solution excluded | Tier 3 with PA/QL | Optum Rx | The exact formulation your prescriber writes matters. Confirm the NDC before submission. |
| NALC Health Benefit Plan (PSHB only) | PA + preferred-alternative requirements | PA with preferred-alternative steering; CVS Weight Management Program required | Preferred under CVS Caremark | CVS Caremark | PA vs. formulary exception varies by clinical scenario. Confirm path with CVS Caremark before your prescriber submits. |
| APWU High Option | Generally available with PA | Prior Authorization | Available with PA | Express Scripts | Friendliest major FEHB path for Zepbound — Express Scripts kept Zepbound on its National Preferred Formulary through 2026. |
| APWU Consumer Driven Option | Verify in OptumRx tool | Prior Authorization typical | Available with PA | OptumRx | Different PBM than High Option. Use APWU CDHP / OptumRx drug tool for your specific tier and cost. |
| Aetna Federal / Aetna Direct | Non-formulary | Formulary Exception required | Preferred | CVS Caremark | Documentation-heavy exception path. Wegovy is the primary formulary alternative. Six-month weight-management program required. |
| FSBP, SAMBA, Rural Carrier, smaller plans | Plan-specific | Varies | Varies | Varies | Use the 4-question script below when calling your plan’s pharmacy line. |
What you read into this matrix matters more than the table itself. “Covered with prior authorization” sounds the same as “formulary exception required” if you don’t know the difference. The next section explains why those two phrases lead to completely different outcomes.
The four words that decide everything: PA, FE, Tier Exception, Excluded
You will hear these four phrases in every conversation about your FEHB Zepbound coverage. They are not interchangeable. Most denials get worse because patients — and even some providers — treat them as if they are.
Prior Authorization (PA)
The drug is on your plan’s formulary. Your insurer wants documentation before they pay — usually BMI, qualifying comorbidity, and prior treatment history. Approval rates are reasonable when criteria are met. PA is the easier path.
Formulary Exception (FE)
The drug is not on your plan’s standard formulary. You’re asking the plan to make a one-off exception. The bar is higher. Most CVS Caremark FEHB plans require BMI criteria, weight-management program participation, no concurrent GLP-1 use, and inadequate response or intolerance to preferred alternatives. Approval rates are noticeably lower than PA.
Tier Exception
A request to move a drug to a lower (cheaper) cost tier. BCBS FEP says no tier exception is allowed for approved GLP-1s. Most other FEHB plans agree. Even if you win a formulary exception, your cost share usually doesn’t change.
Excluded (or Tier E on Compass Rose)
The plan won’t cover the drug under standard rules. Some plans allow exception pathways even from “excluded” status; some don’t. On Compass Rose specifically, Tier E = excluded. The subcutaneous solution form of Zepbound is Tier E on Compass Rose.
Why almost every FEHB plan made Zepbound harder in 2026: the CVS Caremark cascade
- 1May 2025: CVS Caremark and Novo Nordisk strike a rebate deal making Wegovy the preferred GLP-1.
- 2July 1, 2025: Zepbound removed from CVS Caremark’s Standard Control, Advanced Control, and Value formularies. Existing PAs begin migrating to Wegovy. Members get letters.
- 3Fall 2025: FEHB carriers using CVS Caremark publish 2026 brochures reflecting the new structure. GEHA classifies Zepbound as non-formulary across all five plans. BCBS FEP confirms Zepbound is only available through formulary exception. NALC and MHBP follow.
- 4January 1, 2026: Approved formulary exceptions on FEP are recognized through their stated expiration date — your existing exception isn’t automatically canceled. But once it expires, your prescriber needs to resubmit under 2026 criteria.
- 5Throughout 2026: Federal employees on Bogleheads, r/fednews, and r/FedEmployees ask which FEHB plan to switch to. The honest answer — which we’ll get to — is “probably none of them.”
The frustrating truth, said plainly: OPM’s “every FEHB plan must cover at least one GLP-1” rule doesn’t guarantee that your plan makes Zepbound easy or cheap. The OPM mandate is satisfied by Wegovy. If you specifically want tirzepatide, you’re going to have to fight for it on most plans — or pay for it yourself. Once you know which bucket your plan puts Zepbound in, the next step gets very specific.
Plan-by-plan: what each FEHB plan actually does with Zepbound in 2026
BCBS FEP (Blue Standard, Blue Basic, Blue Focus)
BCBS FEP is the largest FEHB carrier. All three plans use CVS Caremark, and all three require a formulary exception for Zepbound in 2026.
- FEP Blue Standard: Zepbound is Tier 3 non-preferred only after a formulary exception is approved. No tier exception allowed.
- FEP Blue Basic: Treated as “Managed Not Covered.” Without an approved exception, members pay full retail. With an approved exception, Zepbound moves to Tier 3 non-preferred.
- FEP Blue Focus: Closed formulary — everything off-list needs an exception first. If approved, Zepbound and Wegovy share Tier 2 Preferred placement — surprisingly good cost share. Note: the FEP Medicare Prescription Drug Program (MPDP) is not available for FEP Blue Focus members.
FEP Blue’s published Zepbound criteria (via CVS Caremark):
- Age 18 or older.
- BMI ≥30, or BMI ≥27 with a weight-related comorbidity.
- Documented inadequate response, intolerance, or contraindication to at least two oral weight-management medications (phentermine/topiramate, naltrexone/bupropion).
- Active participation in a comprehensive weight-management program with reduced-calorie diet and increased physical activity.
- No concurrent GLP-1 or PA-required weight-loss medication use.
- Use of preferred products unless a valid medical exception applies.
- For continuation/renewal: documented weight loss or a clinical reason to continue therapy.
GEHA (High, Standard, HDHP, Elevate, Elevate Plus)
GEHA is the second-largest FEHB carrier and the plan most affected by the 2026 change. GEHA’s published 2026 GLP-1 FAQ explicitly reclassifies Zepbound as non-formulary across all five plans. Wegovy moved to non-preferred on most of them (still preferred on Elevate only).
If you’re a GEHA member who was approved for Zepbound in 2025, check the expiration date on your existing approval. Once it expires, your prescriber needs to submit a fresh formulary exception under 2026 criteria, with the Wegovy step-therapy hurdle in front of it. Provider line: CVS Caremark at 1-844-443-4279.
Kaiser Permanente FEHB (regional)
Kaiser is structurally different from the other big FEHB carriers because Kaiser is its own integrated system — Kaiser is your insurer, your doctor, and your pharmacy. There is no CVS Caremark, so the July 2025 cascade didn’t reach Kaiser members the same way. Kaiser’s all-regions FEHB pharmacy summary states members have access to GLP-1 drugs and oral anti-obesity medications at 50% coinsurance with prior authorization.
What Kaiser’s all-regions document requires:
- Enrollment in a Kaiser lifestyle intervention or guided behavioral program.
- Baseline BMI ≥27 with a weight-related comorbidity (or ≥30 without comorbidity, depending on region).
- Documented intolerance, contraindication, or failure to lose and maintain at least 5% body weight after a 3-month trial of other weight-management medications.
- Monthly in-office visits with weight monitoring.
- Patient attestation to reduced-calorie diet and increased physical activity.
MHBP (Mail Handlers Benefit Plan)
MHBP’s 2026 federal performance drug list shows anti-obesity options including orlistat, Qsymia, Saxenda, and Wegovy. Zepbound is not listed as a standard formulary anti-obesity option. MHBP also requires enrollment in the CVS Weight Management Program to fill weight-loss medication at the plan-designated cost share — an active enrollment, not a paperwork checkbox.
Compass Rose Health Plan
Compass Rose uses Optum Rx. The 2026 formulary makes the Zepbound formulation distinction explicit:
- Zepbound subcutaneous solution: Tier E (Excluded). The drug may not be covered or may need prior authorization for any path forward.
- Zepbound subcutaneous solution auto-injector: Tier 3 with PA and quantity limits. The auto-injector pen is reachable through prior authorization.
NALC Health Benefit Plan (now PSHB only)
NALC HBP became postal-only under the Postal Service Health Benefits Program in 2025. Verified 2026 NALC documentation shows Zepbound on the prior-authorization and limits chart, with the preferred-options table pointing Zepbound users toward orlistat, Qsymia, Saxenda, and Wegovy. CVS Weight Management Program enrollment is required to fill weight-loss medications at the plan-designated cost share.
Whether NALC routes a specific Zepbound request through standard prior authorization versus a formulary exception varies by clinical scenario. Confirm the path with CVS Caremark before your prescriber submits.
APWU Health Plan — the 2026 bright spot
APWU is a quietly important option in 2026 because of how it splits PBMs by plan option:
- APWU High Option uses Express Scripts. The 2026 Express Scripts National Preferred Formulary lists Zepbound Pen — making APWU High one of the friendliest major FEHB options for Zepbound. Coverage still requires PA and you should verify your tier, cost share, and quantity limits in the plan drug tool.
- APWU Consumer Driven Option uses OptumRx. Different PBM, different formulary structure. Use the APWU CDHP / OptumRx drug tool for your specific tier and cost.
Aetna Federal / Aetna Direct
Aetna FEHB plans follow Aetna’s standard commercial pharmacy clinical policy bulletins. Aetna’s published Zepbound Exception policy lists Wegovy as the primary formulary alternative and treats Zepbound as non-formulary. The exception path is documentation-heavy and similar to FEP Blue’s: BMI threshold, comorbidity, six months of structured weight-management program participation, and either Wegovy step therapy or documented contraindication.
FSBP, SAMBA, Rural Carrier, and smaller plans
If your plan isn’t covered above, use this 4-question script when you call your plan’s pharmacy line:
- “Is Zepbound (tirzepatide) on the 2026 formulary, and if so, on which tier?”
- “If Zepbound is non-formulary or excluded, is a formulary exception process available, and what are the criteria?”
- “Is there a step-therapy requirement that I try Wegovy or another GLP-1 first?”
- “What’s my estimated 30-day out-of-pocket cost if my prescriber’s submission is approved?”
Get the answers in writing through your member portal whenever possible. Verbal confirmations from member services aren’t binding.
The fastest way to skip all of this
Ro’s free GLP-1 Insurance Coverage Checker collects your insurance information, contacts your plan, and sends you a personalized coverage report — including whether prior authorization is required and your likely cost share. If you continue with a Ro-affiliated provider, Ro states that its insurance concierge submits prior-authorization paperwork and fights for coverage on your behalf.
Check your FEHB plan’s Zepbound coverage on Ro →How to actually get a Zepbound formulary exception approved
Step 1: Confirm your plan’s exact exception path
BCBS FEP, GEHA, NALC, MHBP, and Aetna each have their own form. Don’t generalize. Each plan’s pharmacy FAQ links the right document.
Step 2: Build your clinical case before the visit
Bring to your prescriber:
- Current weight and height — ideally two clinic-measured values from different visits.
- Diagnoses for weight-related comorbidities (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, cardiovascular disease).
- Pharmacy printouts or chart notes showing prior weight-loss medication trials — what you tried, how long, what happened.
- Documentation of weight-management program participation (Noom, in-clinic counseling, dietitian visits).
- Your previous Zepbound prior authorization or recent denial letter, if you have one.
Step 3: Clear the preferred-alternative hurdle
This is the single biggest reason 2026 exceptions get denied. On most CVS Caremark FEHB plans, the preferred GLP-1 alternative is Wegovy. Three ways through:
- Trial Wegovy. Many people do well on Wegovy. If it works, you don’t need Zepbound — and you’ve spared yourself a fight.
- Document Wegovy intolerance. Severe nausea that didn’t respond to dose adjustment, vomiting, dehydration, gallbladder issues — your prescriber’s notes need to be specific.
- Document Wegovy failure or inadequate response. Confirm the specific criteria with your plan; pharmacy fill records help prove you actually took the medication.
Step 4: Submit electronically when possible
ePA through CoverMyMeds is faster than fax. Most providers have it. Decisions on ePA submissions often come back in 1–7 business days. Fax submissions can take up to 14.
Step 5: If denied, appeal — and most people don’t
Fewer than 1 in 10 patients ever appeal a GLP-1 denial. The success rate when patients do appeal is over 65% on commercial-style plans when the appeal is well-documented. For FEHB members, the OPM Disputed Claims Review process is the final external option after your plan’s internal appeals are exhausted.
What FEHB plans look for: the eligibility criteria you actually have to meet
Approval criteria vary by plan, but the convergence across BCBS FEP, GEHA, Kaiser, and Aetna is striking. Most FEHB plans want:
- ✓BMI ≥30, OR BMI ≥27 with a documented weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, cardiovascular disease, obstructive sleep apnea).
- ✓Documented prior trial of preferred alternatives. On most CVS Caremark plans in 2026, this means Wegovy. FEP specifically requires inadequate response, intolerance, or contraindication to at least two oral weight-management medications.
- ✓Active participation in a comprehensive weight-management program with reduced-calorie diet and increased physical activity. Kaiser requires lifestyle program enrollment; MHBP requires CVS Weight Management Program enrollment.
- ✓No concurrent use of another GLP-1 or PA-required weight-loss medication. You can’t be on Wegovy and Zepbound simultaneously.
- ✓Patient attestation to ongoing dietary and lifestyle modifications.
For continuation past the initial 3- or 6-month approval window, plans want documented weight loss (typically ≥5%) or a documented clinical rationale to continue therapy.
Already on Zepbound and concerned about your 2025 approval? Read this first.
This week:
Pull your most recent fill record. Identify your last Zepbound dose. Find your existing PA or exception approval letter and check the expiration date. Get on your prescriber’s calendar for a telehealth visit to discuss next steps.
Next 14 days:
Decide which path fits you. If you genuinely want to continue Zepbound, your prescriber needs to submit a fresh formulary exception with the documentation listed above before your current approval expires. If you don’t have the documentation to clear the preferred-alternative hurdle, the cleanest move is often to move to LillyDirect self-pay temporarily and rebuild your case.
Within 30 days:
If your decision is “switch to Wegovy,” your prescriber writes the new prescription. CVS Caremark typically migrates active Zepbound PAs to Wegovy automatically — your existing weight-loss program participation may carry over, depending on the plan.
Want a clinician and an insurance team that handles the FEHB paperwork for you?
Ro coordinates the prior-authorization process and routes you to FDA-approved cash-pay options if coverage doesn’t come through. The free coverage checker tells you what your plan does before you commit to anything.
Run the free Ro coverage check before your approval expires →If your plan blocks Zepbound: your three real options (with real numbers)
Option 1: Wegovy — the path of least resistance on FEHB in 2026
Wegovy (semaglutide) is a preferred or listed anti-obesity GLP-1 path on the major CVS Caremark-administered FEHB plans we verified, including FEP, GEHA, MHBP, and NALC. It also has an FDA-approved indication for cardiovascular risk reduction in adults with established CVD and obesity or overweight — Zepbound does not. If you haven’t tried Wegovy yet and your plan steers you toward it, the calmest move is usually to take that path.
Option 2: LillyDirect Self Pay Journey Program — no PA, no formulary fight
LillyDirect is Eli Lilly’s direct-to-consumer pharmacy. The Zepbound Self Pay Journey Program offers active offer pricing as of April 2026:
| Dose | Monthly cost (refill within 45 days) | If 45-day window missed |
|---|---|---|
| 2.5 mg (starting) | $299 | $299 |
| 5 mg | $399 | $399 |
| 7.5–15 mg | $449 | $499–$699 |
No prior authorization is required. No formulary exception. No step therapy. You need a prescription from any licensed prescriber and a credit card. For many federal employees whose plan blocks Zepbound, $449/month cash is often less than paying Tier 3 non-preferred coinsurance against the $1,086/month list price.
Honest disclosure: Ro is not the cheapest possible path for cash-pay Zepbound. If raw price is your only priority, you can buy Zepbound directly from LillyDirect without a Ro membership. Ro charges a separate membership because they offer a full-time prescriber, ongoing care, the insurance concierge if you ever want to try the FEHB route again, and clinical support between fills.
Option 3 (annuitants only): Medicare GLP-1 Bridge — launching July 1, 2026
If you’re a federal annuitant on Medicare Part D, the Medicare GLP-1 Bridge is worth understanding. CMS extended it through December 31, 2027. The Bridge offers eligible Part D beneficiaries access to Foundayo, Wegovy (injection and tablets), and Zepbound KwikPen only (not vials, not single-dose pens) at $50/month.
Bonus: TrumpRx (cash-pay, launched 2026)
TrumpRx is the federal direct-to-consumer pricing platform launched in 2026 at trumprx.gov, listing Zepbound starting at $299/month through LillyDirect fulfillment. This is a cash-pay access and pricing route — same medication, same Lilly fulfillment, different consumer-facing portal. If you’re going self-pay anyway, the price floor is similar to going direct through LillyDirect.
Should you switch FEHB plans during Open Season for Zepbound?
On a CVS Caremark FEHB plan now (BCBS FEP, GEHA, NALC, MHBP, Aetna)?
Switching to another CVS Caremark plan changes nothing about your Zepbound path. You’d be moving paperwork, not access.
Considering switching to APWU High Option?
APWU High on Express Scripts is friendlier for Zepbound specifically, but APWU’s broader benefits package, network, and premium structure has to make sense for your overall situation. Don’t pick a plan for a single drug. APWU CDHP uses OptumRx — a different formulary you’d need to verify separately.
Considering switching to Kaiser?
Two questions: (1) Is Kaiser available in your region with the providers you’d want? (2) Are you comfortable with Kaiser’s integrated model, where Kaiser is your insurer and your doctor and your pharmacy? Kaiser’s PA-based 50% coinsurance is real coverage — but it’s still 50% coinsurance, plus the program friction, plus regional criteria that may be stricter than the all-regions summary suggests.
Considering switching just to stop fighting?
Often the better move is to skip the fight entirely and go LillyDirect self-pay at $299–$449/month. No plan switch required, no exception paperwork, no preferred-alternative trial requirement. You stay on your current FEHB plan for everything else.
The OSA pathway: Zepbound for sleep apnea on FEHB
What you’ll typically need:
- A polysomnogram (sleep study) confirming moderate-to-severe OSA.
- BMI ≥30 in most plans.
- Either inability to tolerate positive airway pressure (CPAP/BiPAP) or documented suboptimal response to PAP therapy — verify your specific plan’s criteria.
- A prescriber willing to submit the OSA-specific prior authorization rather than the weight-management one.
This pathway isn’t a backdoor for everyone — you actually need OSA. But if you have it (and many people with obesity do, often undiagnosed), it can be a legitimate alternative coverage angle that changes the documentation requirements.
Wegovy vs. Zepbound on FEHB in 2026: the honest comparison
| Wegovy (semaglutide) | Zepbound (tirzepatide) | |
|---|---|---|
| FEHB access (2026) | Preferred or listed anti-obesity GLP-1 on major CVS Caremark plans (FEP, GEHA, MHBP, NALC) | Non-formulary on those plans; formulary exception required, with preferred-alternative hurdle |
| Mechanism | GLP-1 receptor agonist | Dual GIP and GLP-1 receptor agonist |
| FDA-approved indications | Chronic weight management; cardiovascular risk reduction in adults with established CVD + obesity/overweight | Chronic weight management; moderate-to-severe OSA in adults with obesity |
| Cardiovascular outcome data | SELECT trial: significant reduction in major adverse cardiovascular events | Cardiovascular outcomes still being studied |
| Self-pay pricing | NovoCare cash pay: $199/month for first 2 months (limited time), then ~$349/month | LillyDirect: $299 (2.5 mg), $399 (5 mg), $449 (7.5–15 mg, refill-timing terms apply) |
| Best fit on FEHB | First-line: easier path, broader insurance coverage, cardiovascular benefit | After preferred-alternative trial fails or is contraindicated, or when paying cash anyway |
For specific weight-loss and clinical efficacy figures, refer to the FDA-approved prescribing information for each medication and discuss expected outcomes with your prescriber — individual results vary based on dose, duration, comorbidity, and adherence to lifestyle changes.
What FEHB members actually pay for Zepbound in 2026
| Path | Approx. 2026 monthly cost | Annual (steady state) | Friction |
|---|---|---|---|
| BCBS FEP Standard with approved FE | ~35% coinsurance on Tier 3; varies by dose & pharmacy | Capped by MPDP $2,100 OOP max if MPDP-enrolled | High |
| GEHA Standard with approved FE | ~$550 (member-reported, not official) | ~$6,600 if no OOP cap relief | High |
| Kaiser Permanente FEHB with PA | 50% coinsurance on plan allowance | Region-dependent | Medium |
| APWU High Option with PA | Varies (Express Scripts) | Plan-dependent | Medium |
| LillyDirect Self Pay (cash) | $299–$449 (refill-timing terms apply) | $3,588–$5,388 | Low |
| TrumpRx (cash, launched 2026) | Starting $299 | ~$3,588–$5,388 | Low |
| Medicare GLP-1 Bridge (annuitants, July 2026+) | $50 | $600 | Medium |
The key insight: In 2026, paying $449/month cash through LillyDirect is often cheaper than paying coinsurance against Zepbound’s ~$1,086/month list price on a Tier 3 non-preferred plan, even with an approved formulary exception. Run the math against your actual cost share before assuming “covered” means “cheap.”
Safety information you need to know before chasing Zepbound coverage
Per Zepbound’s prescribing information, key safety considerations include:
- Contraindications: personal or family history of MTC; MEN 2; known serious hypersensitivity to tirzepatide.
- Pancreatitis risk: acute pancreatitis has been reported.
- Gallbladder disease: acute cholecystitis and cholelithiasis have been reported.
- Acute kidney injury: has occurred, often related to severe GI adverse reactions causing dehydration.
- Hypoglycemia: risk increases when used with insulin secretagogues or insulin.
- Severe gastrointestinal disease: use with caution in patients with pre-existing severe GI disease.
- Diabetic retinopathy: reported in patients with type 2 diabetes.
- Pregnancy: weight loss is not recommended during pregnancy. Discontinue if pregnancy occurs.
- Oral contraceptives: switch to a non-oral method or add a barrier method for 4 weeks after initiation and after each dose escalation.
- No concurrent use: do not use with other tirzepatide-containing products, GLP-1 receptor agonists, or other anti-obesity products.
This is a summary, not the full prescribing information. Always discuss safety, side effects, and individual fit with your prescriber. The full Zepbound prescribing information is available through the FDA and Eli Lilly.
How Ro handles FEHB prior authorization
Ro states that FEHB members can join Ro Body and access its insurance concierge. When you run Ro’s free GLP-1 Insurance Coverage Checker, Ro collects your insurance information, contacts your specific plan, and sends you a personalized coverage report — including whether prior authorization is required and your likely cost share. The form takes a few minutes; the report is sent after Ro completes the insurance check.
If you continue with a Ro-affiliated provider, Ro states that its insurance concierge submits prior-authorization paperwork on your behalf, fights for coverage, handles denials, and — if all coverage paths fail — routes you to FDA-approved cash-pay options (Wegovy through NovoCare, Zepbound KwikPen through LillyDirect) without confusing them with compounded medications.
“…handling all the insurance…” — Colleen B., Ro member
“…easy for me to voice my concerns…” — Kristen B., Ro member
$39 first month · as low as $74/mo annual · concierge handles FEHB paperwork
Disclosure: We may earn a commission if you sign up with Ro. Our coverage analysis is based on plan and PBM documents, not affiliate status.
What we actually verified for this page
Per The RX Index editorial standard, here’s exactly what was checked, when, and how. We refresh this page quarterly and during every Open Season.
Verified by reading published source documents on :
- OPM 2023 carrier letter and 2026 Open Season program-level requirements for anti-obesity medication coverage in FEHB and PSHB.
- BCBS FEP 2026 pharmacy FAQ, formulary exception structure, Zepbound tier placement, and provider phone numbers (fepblue.org).
- CVS Caremark FEP Zepbound clinical criteria PDF (info.caremark.com).
- GEHA 2026 GLP-1 FAQ — reclassifying Zepbound as non-formulary across all five plans (geha.com).
- Kaiser Permanente FEHB all-regions 2026 pharmacy summary and Kaiser Northwest 2026 Zepbound-specific criteria (kaiserpermanente.org).
- MHBP 2026 brochure, federal performance drug list, and CVS Weight Management Program enrollment requirements (mhbp.com).
- Compass Rose 2026 formulary — confirming Tier E exclusion for subcutaneous solution and Tier 3/PA for auto-injector (compassrose.com).
- NALC 2026 pharmacy and PA documentation (nalchbp.org).
- APWU 2026 Express Scripts National Preferred Formulary (expressscripts.com).
- Aetna commercial pharmacy clinical policy bulletin — Zepbound Exception policy (aetna.com).
- LillyDirect Zepbound Self Pay Journey Program pricing (zepbound.lilly.com/self-pay).
- CMS Medicare GLP-1 Bridge announcement and extension notice (cms.gov).
- Zepbound FDA-approved prescribing information and boxed warning (accessdata.fda.gov).
- Ro Body membership pricing and insurance concierge service description (ro.co).
Frequently asked questions
- Does FEHB cover Zepbound in 2026?
- Yes — conditionally. Every FEHB plan must cover at least one FDA-approved anti-obesity GLP-1, but most major plans satisfy that mandate with Wegovy, not Zepbound. In 2026, Zepbound requires a formulary exception on BCBS FEP, GEHA, MHBP, and most Aetna FEHB plans (all CVS Caremark). Kaiser FEHB covers Zepbound with prior authorization at 50% coinsurance; rules vary by region. APWU High Option on Express Scripts is the most favorable major FEHB path for Zepbound specifically.
- Does BCBS FEP cover Zepbound in 2026?
- Conditionally, through a formulary exception only. FEP Blue Standard places Zepbound at Tier 3 non-preferred after an approved formulary exception. FEP Blue Basic treats it as 'Managed Not Covered' — without an exception, members pay full retail. FEP Blue Focus has a closed formulary; an exception is required, but if approved, both Zepbound and Wegovy share Tier 2 Preferred placement. No tier exception is allowed on any FEP Blue plan.
- Does GEHA cover Zepbound in 2026?
- Conditionally. GEHA reclassified Zepbound as non-formulary across all five plans (High, Standard, HDHP, Elevate, Elevate Plus) for 2026. A formulary exception is required on all of them. Members who had a 2025 Zepbound approval should check its expiration date — a new formulary exception under 2026 criteria is required once it lapses. CVS Caremark provider line: 1-844-443-4279.
- What is a formulary exception for FEHB?
- A formulary exception is a formal request asking your plan to cover a drug that is not on its standard formulary. It is a higher bar than prior authorization. Most CVS Caremark FEHB plans in 2026 require documentation of BMI criteria, a weight-management program, no concurrent GLP-1 use, and inadequate response, intolerance, or contraindication to preferred alternatives (usually Wegovy). Approval rates are noticeably lower than standard prior authorizations.
- Which FEHB plan is best for Zepbound coverage in 2026?
- APWU High Option is the friendliest major FEHB plan for Zepbound in 2026 because it uses Express Scripts, which kept Zepbound on its National Preferred Formulary through 2026. Standard prior authorization is required, not a formulary exception. Kaiser Permanente FEHB is the second-best option for members in Kaiser markets — it uses its own internal pharmacy (not CVS Caremark) and covers GLP-1s with prior authorization at 50% coinsurance, though Zepbound-specific criteria vary by region.
- Does Kaiser FEHB cover Zepbound in 2026?
- Generally yes, with prior authorization and 50% coinsurance of the plan allowance — but Zepbound-specific rules vary significantly by Kaiser region. Kaiser's all-regions FEHB summary covers GLP-1 access with PA at 50% coinsurance. Kaiser Northwest, for example, treats Zepbound as non-formulary requiring clinical review with tighter regional criteria. Verify your specific Kaiser region's Zepbound criteria before assuming coverage.
- Does APWU cover Zepbound in 2026?
- APWU High Option uses Express Scripts, which lists Zepbound Pen on its 2026 National Preferred Formulary. Standard prior authorization is required. This makes APWU High Option one of the friendliest major FEHB paths for Zepbound. APWU Consumer Driven Option uses OptumRx — a different PBM with a different formulary structure. Verify your tier and cost share separately if you're on the CDHP.
- What does Zepbound cost on FEHB in 2026?
- Costs vary widely by plan and path. BCBS FEP Standard with an approved formulary exception: roughly 35% coinsurance on Tier 3, before any out-of-pocket maximum. GEHA Standard with an approved exception: federal employee forum users have reported approximately $550/month (member-reported, not official — verify with your plan). Kaiser FEHB: 50% coinsurance on the plan allowance. LillyDirect self-pay: $299–$449/month with no prior authorization. In many cases, LillyDirect cash-pay is cheaper than paying Tier 3 coinsurance against the $1,086/month list price.
- Can I get Zepbound without FEHB coverage?
- Yes. LillyDirect's Zepbound Self Pay Journey Program offers $299/month (2.5 mg), $399/month (5 mg), or $449/month (7.5–15 mg, when refills are completed within 45 days) with no prior authorization. You need a prescription from any licensed provider and a credit card. No insurance fight, no preferred-alternative hurdle, no formulary exception. For many federal employees whose plan denies Zepbound, LillyDirect self-pay is faster and often cheaper than fighting for partial insurance coverage.
- Does FEHB cover Zepbound for sleep apnea?
- Zepbound received FDA approval for moderate-to-severe obstructive sleep apnea in adults with obesity in December 2024. Some FEHB plans maintain separate prior-authorization criteria for the OSA indication. Coverage for the OSA indication is plan-specific. Don't assume the OSA path automatically avoids preferred-product or step-therapy requirements — some plans we reviewed maintain step-therapy even on the OSA pathway. You will need a polysomnogram confirming moderate-to-severe OSA, BMI ≥30 in most plans, and documented intolerance or suboptimal response to PAP therapy.